Vertex Pharmaceuticals Incorpor

Vertex Pharmaceuticals develops and commercializes therapies for cystic fibrosis (CF) and other diseases. Products include TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO. The pipeline includes VX-522 for CF, VX-548 for pain, Exa-cel for sickle cell disease and beta thalassemia, and others. Inaxaplin treats APOL1-mediated glomerulosclerosis and hypertension. Vertex also develops treatments for Type 1 Diabetes, cancer, and Duchenne muscular dystrophy with various partners. The company sells products to specialty pharmacies and distributors in the US and abroad. Founded in 1989, Vertex is headquartered in Boston, Massachusetts.

Overview

Sector

Biotechnology

Target Price

11.0 USD

Current Price

417.2 USD

Potential

-97%

Strengths

The company has low debt. Net Debt to EBITDA Ratio is -5.81 and it is lower than the sector mean.

Weaknesses

With a depreciation Potential of -97.37%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EV/EBITDA (214.86) is significantly higher than the sector mean (85.60).
EV/EBIT (373.98) is significantly higher than the sector mean.
EBITDA Margin (4.41%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	214.9
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	-5.8

Vertex Pharmaceuticals Incorpor

Overview

Strengths

Weaknesses

Key Financial Data